My first article for Forbes was published about 10 days ago where I profiled how to piggyback Seth Klarman.
The first stock we talked about was Facet Biotech, which just got bought today by Abbott for $27/share or a 67% premium.
My favorite part of the Forbes article is how the only comment was about how “worthless” it was to follow Klarman through 13F filings. Indeed.